Showing results (31-40 of 66) with videos related to
Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|January 3, 2016
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)Konstantinos Tryfonidis, Gul Basaran, Jan Bogaerts, et al.Breast Cancer Research and Treatment|May 20, 2008
Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902Johanna G H van Nes, Hein Putter, Jean-Pierre Julien, et al.Psycho-Oncology|September 17, 2013
Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98Elżbieta Senkus, Henry Gomez, Luc Dirix, et al.The Lancet. Oncology|February 28, 2009
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient dataStefan Michiels, Aurélie Le Maître, Marc Buyse, et al.Journal of Cancer Policy|December 21, 2025
INNOVATIVE ONCOLOGY TRIAL DESIGNS: TIME TO ACT A review with recommendations of the Cancer Drug Development ForumRosa Giuliani, Nafsika Kronidou-Horst, Christina Yap, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2006
Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group, , Nina Bijker, et al.Breast Cancer Research and Treatment|July 29, 2008
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation studyStella Mook, Marjanka K Schmidt, Giuseppe Viale, et al.Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.ESMO Open|October 26, 2017
Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rulesUrania Dafni, Dimitris Karlis, Xanthi Pedeli, et al.Breast (Edinburgh, Scotland)|May 24, 2023
Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohortJosephine M N Lopes Cardozo, Sherylene E Veira, Laila Ait Hassou, et al.Pageof 7